This segment focuses on the research, development, and clinical trials of autologous tumor infiltrating lymphocyte (TIL) therapies. Instil Bio engineers a patient's own T-cells to recognize and attack cancer cells. R&D activities include identifying and isolating TILs, expanding them ex vivo, and infusing them back into the patient. Technologies used include cell culture, flow cytometry, and genetic engineering. Therapeutic areas include melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. The goal is to improve patient outcomes by providing targeted and effective cancer treatments. Market positioning is as a clinical-stage biopharmaceutical company with a focus on cell therapy. Future opportunities include expanding the TIL platform to treat additional cancer types and improving the efficacy of TIL therapies through combination treatments. Clinical trials are a key aspect of this segment, with regulatory compliance and FDA approval being critical for advancing product candidates.

This segment involves the research and development of bispecific antibodies, such as AXN-2510, a PD-L1xVEGF bispecific antibody. The R&D activities include identifying and validating targets, engineering the antibodies, and conducting preclinical and clinical studies. Technologies used include antibody engineering, protein expression, and various in vitro and in vivo assays. The therapeutic focus is on solid tumors, particularly non-small cell lung cancer (NSCLC). The aim is to provide innovative cancer therapies with improved efficacy and safety profiles. Market positioning is enhanced through strategic partnerships, such as the collaboration with ImmuneOnco. Future opportunities include expanding the bispecific antibody pipeline and exploring combination therapies. Regulatory and clinical aspects include conducting Phase 1 and Phase 2 trials and obtaining FDA clearance for IND applications.